Dupixent scores speedy review for rhinosinusitis with nasal polyps; After transplant, third patient is HIV-free for 3 months
→ Regeneron $REGN and Sanofi’s $SNY monoclonal antibody Dupixent — already approved for eczema and asthma — is in line for another approval. The FDA has granted the drug — which made $922 million in net sales last year — priority review for patients with severe chronic rhinosinusitis with nasal polyps, who often see their disease return despite surgery and/or systemic corticosteroids. The US agency is expected to make its decision by June 26.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.